In a new job - October 28, 2021
Immunicum recruits new Chief Financial Officer
Immunicum has announced the appointment of Lotta Ferm as Chief Financial Officer (CFO) effective as of November 1, 2021. Lotta Ferm has been acting as Immunicum’s interim CFO since February of this year and will continue to lead the company’s finance and HR activities. “Since her appointment as interim CFO, Lotta has been responsible for […]
Biotech Business - July 1, 2021
Immunicum receives Advanced Therapy Medicinal Product classification
The company has received Advanced Therapy Medicinal Product (ATMP) classification from the European Medicines Agency (EMA) for the company’s lead cancer relapse vaccine candidate, DCP-001. DCP-001 is derived from Immunicum’s human DCOne cell line and is currently being evaluated as a cancer relapse vaccine for the prevention of tumor recurrence in two ongoing clinical studies […]
Clinical Trials - June 23, 2021
First patient enrolled in Immunicum’s ALISON study
The Phase I clinical study evaluates DCP-001, the company’s lead cancer relapse vaccine candidate, in High-Grade Serous Ovarian Cancer (HGSOC) patients following primary standard of care treatment. The ALISON study is carried out by Professor Hans Nijman and his research group in Groningen, the Netherlands, and investigates the ability of DCP-001 to trigger the immune […]
Collaboration - April 14, 2021
Immunicum enters research collaboration
Immunicum has announced the initiation of a research collaboration with the laboratory of Nina Bhardwaj, Director of Immunotherapy and the Medical Director of the Vaccine and Cell Therapy Core Facility, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York City. Dr. Bhardwaj is a leading researcher who has made significant […]
Careers article - March 16, 2021
Immunicum announces updated executive management team
Immunicum has announced the establishment of an updated executive management team following the initial integration period of the business combination with DCprime that was completed in December 2020. In the new composition, the executive management team consists of Erik Manting, Ph.D., as Chief Executive Officer (CEO), Lotta Ferm as Interim Chief Financial Officer (CFO), Alex […]
In a new job - March 7, 2021
Immunicum appoints new Chief Medical Officer
Immunicum has announced that Jeroen Rovers, M.D., Ph.D., has been appointed to the position of Chief Medical Officer (CMO). Rovers transitions from his role as Managing Director of DCprime and continues to serve on Immunicum’s management team. Peter Suenaert, M.D., Ph.D., current CMO of Immunicum, will remain with the company as clinical advisor, continuing to […]
